Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?

Journal of Clinical Psychiatry

Volumn 73, Issue 11, 2012, Pages 1439-1442

  Perlis, Roy H ^a   Uher, Rudolf ^b,c   Perroud, Nader ^d   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c DALHOUSIE UNIVERSITY   (Canada)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; SERTRALINE; VENLAFAXINE;

ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; HUMAN; MAJOR DEPRESSION; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; SCORING SYSTEM; SUICIDAL BEHAVIOR;

EID: 84869222319     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07777     Document Type: Article

References (17)

1. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339(2):b2880. doi:10.136/bmj.b280 PubMed
2. Food and Drug Administration. Suicidality and antidepressant labeling: revisions to product labeling. http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM173233.pdf. Accessibility verified July 18, 2012.
3. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007;64(6):689-697. doi:10.101/archpsyc.64.6.689 PubMed (Pubitemid 46878669)
4. Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. BMC Med. 2009;7(1):60. doi:10.186/1741-7015-7-60 PubMed
5. Perlis RH, Beasley CM Jr, Wines JD Jr, et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom. 2007;76(1):40-46. doi:10.159/096363 PubMed (Pubitemid 46005718)
6. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338-343. doi:10.101/jama.292.3.38 PubMed (Pubitemid 38944257)
7. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996; 26(3):477-486. doi:10.1017/S0329170358 PubMed (Pubitemid 26142491)
8. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142. doi:10.1016/S0197-2456(03) 012-0 PubMed (Pubitemid 38230109)
9. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. doi:10.176/api.ajp.163.1.28 PubMed (Pubitemid 43050100)
10. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50(10):792-801. doi:10.1016/S06-323(01)0123-9 PubMed (Pubitemid 33086767)
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
12. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-659. doi:10.1016/S06-323(03)0231-2 PubMed (Pubitemid 39658481)
13. Kraemer HC, Stice E, Kazdin A, et al. How do risk factors work together? mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry. 2001;158(6):848-856. doi:10.176/api.ajp.158.6.848 PubMed (Pubitemid 32547610)
14. Leon AC. Two clinical trial designs to examine personalized treatments for psychiatric disorders. J Clin Psychiatry. 2011;72(5):593-597. doi:10.408/JCP.09com0581whi PubMed
15. Perroud N, Aitchison KJ, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology. 2009;34(12):2517-2528.
16. Center for Drug Evaluation and Research (CDER). Suicidality: Prospective Assessment of Occurrence in Clinical Trials. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM225130.pdf. Updated August 25, 2010. Accessed June 29, 2012.
17. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043. doi:10.176/api.ajp.164.7.1035 PubMed (Pubitemid 47121392)